Good news! Jusbio Sciences Has Been Awarded the "Technology Little Giant" in Shanghai
On March 10, 2025, the Shanghai Municipal Commission of Science and Technology announced the list of Shanghai Science and Technology Little Giant (including cultivation) enterprises for 2024. Jusbio Sciences was approved for project approval and was awarded the title of "Science and Technology Little Giant" in Shanghai.
The Shanghai Science and Technology Little Giant Project aims to further promote independent innovation of technology-based small and medium-sized enterprises and enhance their core competitiveness. The project implementation target refers to technology-based enterprises engaged in the development, production, operation, and technical (engineering) services of high-tech products that conform to the national and local industrial development direction, with strong scientific and technological innovation capabilities, outstanding market competitive advantages, and great development potential. Its characteristics are innovation, scale, and demonstration. After strict evaluation at all levels, 48 technology small giant enterprises and 70 technology small giant cultivation enterprises were finally approved city wide this year.
Jusbio Sciences was first approved as a technology giant cultivation enterprise in 2022 and passed the comprehensive performance evaluation with "good" results in 2024. The successful establishment of the "Technology Little Giant" enterprise represents the company's excellent performance in terms of innovation capability, independent intellectual property rights, market competitiveness in segmented fields, economic scale and growth, credit record and financing ability.
In the future, Jusbio Sciences will continue to focus on the research and transformation of original biomarkers. Through innovative cooperation models in medical research and production, it will transform the latest clinical research achievements at home and abroad into IVD diagnostic reagents and related instruments and equipment, serving major medical institutions across the country, and continuously enhance industry competitiveness and build industry influence.